荃信生物-B:深耕自免领域 单抗双抗全面布局

华创证券
Sep 13

荃信生物(2509.HK)成立于2015 年,并于2024 年3 月20 日在港交所上市;是一家专注于自身免疫及过敏性疾病生物疗法的生物科技公司,全面覆盖自身免疫疾病的四个主要疾病领域,即皮肤病、风湿病、呼吸系统和消化系统疾病。1.0 管线:乌司奴类似药国产首个上市,单抗布局全面。公司基于完整的自主创新能力已形成多个创新品种的产品管线,其中与华东医药合作的乌司奴类似药赛乐信?已于2024 年10 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10